Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization

David D’Andrea1 · Mohammad Abufaraj1,2 · Francesco Soria1,3 · Kilian Gust1 · Andrea Haitel4 · Pierre I. Krakiewicz5 · Shahrokh F. Shariat1,6,7,8,9

Received: 1 January 2019 / Accepted: 11 April 2019 / Published online: 20 April 2019
© The Author(s) 2019

Abstract

Purpose We performed a retrospective analysis of patients treated with radical cystectomy and lymphadenectomy (LAD) for bladder cancer to assess the differential association of the extent of LAD with perioperative complications and re-hospitalization.

Materials and methods LAD templates were defined as limited (lLAD = external, internal iliac and obturator), extended (eLAD = up to crossing of ureter and presacral lymph nodes), and super-extended (sLAD = up to the inferior mesenteric artery). Logistic regression models investigated the association of LAD templates with intraoperative, 30- and 30–90-day postoperative complications, as well as re-hospitalizations within 30 and 30–90 days.

Results A total of 284 patients were available for analysis. sLAD led to a higher lymph-node yield (median 39 vs 13 for lLAD and 31 for eLAD, p < 0.05) and N2/N3 status compared to lLAD and eLAD (p = 0.04). sLAD was associated with a blood loss of > 500 ml (OR 1.3, 95% CI 1.08–1.49, p = 0.003) but not with intraoperative transfusion, operation time, or length of hospital stay (p > 0.05). Overall, 11 (4%) patients were readmitted within 30 days and 50 (17.6%) within 30–90 days. The 30- and 30–90-day mortality rates were 2.8% and 1.4%, respectively. On logistic regression, LAD template was not associated with postoperative complications or re-hospitalization rates.

Conclusions sLAD leads to higher lymph-node yield and N2/N3 rate but not to higher complication rate compared to lLAD and eLAD. With the advent of novel adjuvant systemic therapies, precise nodal staging will have a crucial role in patients counseling and clinical decision making.

Keywords Bladder cancer · Radical cystectomy · Lymphadenectomy · Complications

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00345-019-02769-9) contains supplementary material, which is available to authorized users.
Introduction

Radical cystectomy (RC) with lymphadenectomy (LAD), preceded by neoadjuvant chemotherapy (NAC) when possible, is the standard of care for muscle-invasive and recurrent high-risk bladder cancer (BCa) [1]. A properly done LAD allows accurate staging and may improve oncologic outcomes, since lymph-node metastases are present in up to 25% of patients treated with RC for muscle-invasive BCa [2–4]. However, the extent of LND is still under debate and the association of the extent of the LND templates with survival remains controversial [5]. In particular, the benefits of a super-extended LAD (sLAD) are questioned, as lymph-node metastasis above the aortic bifurcation is uncommon and the dissection of these nodes could result in longer operative times. Indeed, adverse events and increased complications can occur more frequently in more extensive LAD templates, potentially compromising quality of life in this population that is elderly in general [6–10]. The association of a more extensive LAD template with perioperative complications has not been sufficiently assessed, to our knowledge. Results from a recent randomized trial failed to show any significant differences in 30- and 90-day complications rates between extended LAD (eLAD) and sLAD [10]. However, this study did not report intraoperative complications and re-hospitalization rates. We hypothesized that a more extended LND would be associated with a higher rate of intra- and postoperative complications, length of stay, and re-admissions. To address this, we performed a detailed analysis of perioperative complications and investigated their association with different LAD templates.

Materials and methods

Patient selection

Following institutional review board approval (ID 2168/2017), we reviewed our institutional database to identify patients treated with RC and LAD for clinically non-metastatic BCa. Patients were considered non-metastatic if preoperative imaging did not show spread from the primary site to other places in the body. Patients with missing information regarding postoperative complications within 90 days and those who did not receive all oncologic care at our institution were excluded from the analysis.

Intervention and pathological analysis

Patients were treated with RC and LAD according to guideline recommendations at the time [1]. RC was performed by different surgeons. All procedures were performed by an open technique. The decision for the type of urinary diversions was based on disease characteristics, patient’s wishes, and performance status. The extent of LAD was at the surgeon’s discretion. We defined 12 LAD regions. The limited template (ILAD) included bilateral internal iliacs, external iliacs, and obturator regions; the extended template (eLAD) included ILAD plus up to the crossing of the ureter on the common iliac vessels and presacral region; and the super-extended template (sLAD) included the eLAD plus up to the inferior mesenteric artery in addition to, paracaval and para-aortal regions (Fig. 1). Specimens were analyzed by two dedicated genitourinary pathologists.

Follow-up

Due to the retrospective nature of the study, the follow-up was not standardized, but was in accordance with the guidelines at the time. In general, patients underwent physical examination, ultrasonography, whole body imaging including CT with contrast or MRI as well as bone scan when indicated, and laboratory testing and at physician discretion based on patient and disease risk. Postoperative complications were assessed using the Clavien–Dindo classification [11]. Complications were recorded within 30 days after surgery and between 31 and 90 days after surgery. Major complications were defined as Clavien–Dindo ≥ 3. Cause of
death was recorded based on chart and/or death certificate review [12].

Statistical analyses

Means and standard deviations or median and interquartile range values are reported for normally or non-normally distributed continuous variables, respectively. Differences between proportions were reported using the Chi-square and the Mann–Whitney U test. We built logistic regression models to investigate the association of major postoperative complications as well as intraoperative complications with the LAD template used. Statistical significance was considered at a p < 0.05. All tests were two-sided. Statistical analyses were performed using R (R project, Vienna, Austria).

Results

We identified 434 patients treated with RC within our institutional database. A total of 284 patients had sufficient data available for analysis. Clinicopathologic features are depicted in Table 1. Overall, 200 (70.4%) were treated with ILAD, 34 (12%) with eLAD, and 50 with sLAD (17.6%). The use of sLAD increased with time (Fig. 2). This was associated with an increase in lymph nodes harvested (median nodes harvested 13 vs 31 vs 39 for ILAD, eLAD, and sLAD, respectively). sLAD was significantly associated with a higher incidence of N2 and N3 status at RC compared to ILAD and eLAD (p = 0.04). In subgroup analysis, the receipt of NAC in patients treated with sLAD was not associated with pN+ status (OR 1.16, 95% CI 0.89–1.52).

Regarding perioperative outcomes, sLAD was associated with a blood loss of > 500 ml compared to ILAD and eLAD (OR 1.3, 95% CI 1.07–1.59, p = 0.003). However, it did not affect the number of intraoperative transfusions, operation time, or length of stay (all p > 0.05). On multivariable analysis which adjusted for the effect of age-adjusted Charlson comorbidity index (CCI), tumor stage, body mass index (BMI), and the use of enhanced recovery after surgery (ERAS) protocol, sLAD remained associated with a blood loss of > 500 ml (OR 1.21, 95% CI 1.01–1.44, p = 0.03).

Overall, 30- and 30–90-day complication rates were 61.3% and 49.4%, respectively. Major complications occurred within 30 and 30–90 days in 75 (26.4%) and 41 (14.4%) patients, respectively. The 30- and 30–90-day mortality rates were 2.8% and 1.4%, respectively. A detailed distribution of postoperative complications is depicted in Tables 2 and s1. On logistic regression models, LAD template was not associated with postoperative major complications (p > 0.05) (Table 2). A total of 49 (17.2%) patients experienced a postoperative ileus within 30 days. On univariable logistic regression analyses, sLAE was associated with a lower risk of ileus (OR 0.89, 95% CI 0.79–0.99, p = 0.04). However, on multivariable analyses which adjusted for the effects of patient age, BMI, and the use of ERAS protocol, this association disappeared.

In all, 11 (4%) patients were readmitted within 30 days and 50 (17.6%) within 30–90 days after RC. On logistic regression models, unscheduled hospitalization rates within 30 and 30–90 days were not associated with the LAD template used (p > 0.05) (Table 3).

On exploratory analyses, we investigated the association of clinical features and performance scores with major complications and hospitalization. On logistic regression analysis, age (OR 1.03, 95% CI 1.01–1.06, p = 0.01) and CCI (OR 1.19, 95% CI 1.03–1.37, p = 0.01) were associated with 30-day major complications. Moreover, CCI (OR 1.24, 95% CI 1.05–1.47, p < 0.001) was associated also with 90-day major complications. BMI was associated with 30-day readmission (OR 1.14, 95% CI 1.01–1.27, p = 0.02) (Table 4).

Discussion

We investigated perioperative complications and hospitalization rates associated with ILAD, eLAD, and sLAD using data originating from a tertiary referral center. We found that two-thirds of patients experienced any type of complication and one-third had at least one major complication within 30 days after RC. Our results corroborate those reported in retrospective studies and prospective trials [3, 5, 9, 10, 13–15]. To our knowledge, this is the first study investigating the association of ILAD, eLAD, and sLAD with perioperative outcomes. We reject our null hypothesis, as we failed to observe an association between the extent of LAD template and perioperative complications. Importantly, the previous reports did not investigate the impact of LAD template on surgical morbidity. A retrospective multicenter series investigated the association of LAD with survival outcomes. Authors could not show a significant difference between eLAD and sLAD. However, no postoperative outcomes were reported [9]. Results from the first RCT comparing ILAD vs sLAD did not show significant difference in terms of recurrence-free survival between groups. On exploratory analyses, mortality and major complications (Clavien–Dindo ≥ 3) occurring within 30 and 90 days did not differ between groups [10].

We found that re-hospitalization rates were lower than those reported in large series (19.6% vs > 40%) [16, 17]. However, the comparative data originate from population-based databases including different hospitals. Indeed, data from high-volume tertiary care centers revealed similar re-hospitalization rates compared to ours [3, 18].
While clinicopathologic features and comorbidity indices have been associated with hospitalization [3, 18], studies investigating this association with LAD templates are missing. We filled this gap using logistic regression models.

|                  | Limited LAD | Extended LAD | Super-extended LAD | p      |
|------------------|-------------|--------------|--------------------|--------|
| Age, median (IQR)| 67 (61–74)  | 65 (62–73.7) | 68 (57.5–75.7)     | 0.92   |
| Male gender (%)  | 158 (79.0)  | 25 (73.5)    | 37 (74.0)          | 0.63   |
| BMI, median (IQR)| 25.8 (22.9–27.96) | 26.4 (23.9–29.7) | 25.9 (22.4–27.96) | 0.26   |
| Charlson comorbidity index, median (IQR) | 5 (4–7) | 6 (4.2–8) | 5 (4–8) | 0.22 |
| Preoperative hydronephrosis, n (%) | <0.01 |
| No               | 41 (20.5)   | 12 (35.3)    | 32 (64.0)          |        |
| Yes              | 13 (6.5)    | 9 (26.5)     | 17 (34.0)          |        |
| NA               | 146 (73.0)  | 13 (38.2)    | 1 (2.0)            |        |
| pT, n (%)        | 0.01 |
| NMIBC            | 47 (23.5)   | 9 (26.5)     | 14 (28.0)          |        |
| T0               | 1 (0.5)     | 1 (2.9)      | 5 (10.0)           |        |
| T2               | 57 (28.5)   | 8 (23.5)     | 11 (22.0)          |        |
| T3               | 62 (31.0)   | 10 (29.4)    | 17 (34.0)          |        |
| T4               | 33 (16.5)   | 6 (17.6)     | 3 (6.0)            |        |
| pN, n (%)        | 0.04 |
| N0               | 143 (71.5)  | 25 (73.5)    | 33 (66.0)          |        |
| N1               | 23 (11.5)   | 4 (11.8)     | 3 (6.0)            |        |
| N2               | 33 (16.5)   | 4 (11.8)     | 10 (20.0)          |        |
| N3               | 1 (0.5)     | 1 (2.9)      | 4 (8.0)            |        |
| Lymph nodes removed, median (IQR) | <0.01 |
| STSM, n (%)      | 0.28 |
| R0               | 174 (87.0)  | 29 (85.3)    | 43 (86.0)          |        |
| R1               | 26 (13.0)   | 4 (11.8)     | 6 (12.0)           |        |
| Rx               | 0 (0.0)     | 1 (2.9)      | 1 (2.0)            |        |
| Variant histology, n (%) | <0.01 |
| Absent           | 175 (87.5)  | 22 (64.7)    | 32 (64.0)          |        |
| Mixed            | 15 (7.5)    | 11 (32.4)    | 12 (24.0)          |        |
| Pure             | 6 (3.0)     | 1 (2.9)      | 4 (8.0)            |        |
| NA               | 4 (2.0)     | 0 (0.0)      | 2 (4.0)            |        |
| Diversion, n (%) | 0.03 |
| UUCS             | 13 (6.5)    | 1 (2.9)      | 1 (2.0)            |        |
| Colon conduit    | 4 (2.0)     | 0 (0.0)      | 0 (0.0)            |        |
| Ileum conduit    | 127 (63.5)  | 30 (88.2)    | 43 (86.0)          |        |
| Ileum neobladder | 54 (27.0)   | 3 (8.8)      | 5 (10.0)           |        |
| No diversion*    | 2 (1.0)     | 0 (0.0)      | 1 (2.0)            |        |
| NAC (%)          | 2 (1.0)     | 2 (5.9)      | 21 (42.0)          | <0.01  |
| Days of hospital stay, median (IQR) | 0.01 |
| Transfusion rate, median (IQR) | 0.71 |
| Estimated blood loss (ml), median (IQR) | 0.08 |
| Operation time (min), median (IQR) | 0.99 |

IQR interquartile range, BMI body mass index, STSM soft tissue surgical margin, UUCS uretero-uretero-cutaneostomy, NAC neoadjuvant chemotherapy, NA not available

*aNo diversion necessary because of chronic hemodialysis
We did not find any difference in operative times between different LAD templates. Retrospective series reported controversial results [13, 19]. The operative time depends on the surgeon, different LAD templates, previous surgeries, and other factors affecting the surgical site; all of these may have influenced these results. We have adopted sLAD in more recent years, reflecting the improvement of the surgical technique and a change in surgical paradigm over the years. Although the sLAD cohort had higher blood loss, this was not associated with higher transfusion rates [13]. Various factors can affect blood loss such as comorbidities, surgical approach and technique, disease severity as well as measurement of blood loss. To our knowledge, no previous studies have reported on blood loss in patients who underwent sLND.

LAD is an essential compound of RC necessary for accurate staging and, potentially, for disease control [5]. A recent RCT from Germany highlighted this issue reporting a 2% rate of lymph-node metastases outside the lLAD [10]. In our series, four patients (8%) treated with sLAD had lymph-node metastases outside the ILAD and eLAD template. These patients would have been, therefore, understaged if no sLAD would have been performed. Moreover, we found higher rates of pN3 compared to this trial (2.1% vs 0.5%). However, these results must be interpreted in the context of the retrospective design and the lack of pathologic review. It is, however, true that our series includes patients with clinically more evolved disease than the German RCT.

Identification of preoperative risk factors for hospitalization is of paramount importance for patients’ management and counseling. In line with the previous reports, we identified advanced age and high CCI to be associated with the risk of major postoperative complications [13, 14, 19]. However, these studies did not investigate the association of LAD...
extent with outcomes. This is a relevant shortcoming, as omitting surgical steps can obviously influence perioperative outcomes. To overcome these limitations, we performed a detailed analysis of complications associated with different LADs and showed that a more extensive LAD is not associated with higher perioperative morbidity, while this is associated with a better disease staging. Whether the extent of LAD is associated with cure rates and survival remains to be assessed in ongoing prospective RCTs (i.e., SWOG 1011).

Nevertheless, RC remains a procedure associated with high perioperative complication rates due to the procedure itself, patients’ comorbidities and tumor characteristics. It is, therefore, of paramount importance to balance potential benefits of a more extended LAD and counsel patients for a risk-adapted approach. In this context, one-fits-all approach using a unified template for all patients is not optimal and can be considered an overtreatment in a significant number of patients [6, 7]. There is an unmet need for better patient selection and development of clinical tool which may aid in

**Table 3** Distribution and logistic regression analysis for the association of hospitalization rates with the lymphadenectomy (LAD) template used in 284 patients treated with radical cystectomy for clinically non-metastatic bladder cancer

|                      | Hospitalizations within 30 days |          | Hospitalizations within 30–90 days |          |
|----------------------|---------------------------------|----------|-----------------------------------|----------|
|                      | N (95% CI)                      | OR (95% CI) | p | N (95% CI)                      | OR (95% CI) | p |
| Limited LAD          | 6 (2.25%)                       | Ref.     | 34 (13.1%)                       | Ref.     |
| Extended LAD         | 3 (1.13%)                       | 1.06 (0.99–1.45) | 0.1 | 4 (1.5%)                       | 0.95 (0.81–1.11) | 0.5 |
| Super-extended LAD   | 2 (0.75%)                       | 1.01 (0.95–1.08) | 0.7 | 13 (5%)                       | 1.5 (0.71–3.19) | 0.2 |

**Table 4** Logistic regression analyses investigating the association of clinical features with major postoperative complications (Clavien–Dindo ≥ 3) and hospitalization in 284 patients treated with radical cystectomy for clinically non-metastatic bladder cancer

|                      | 30-day major complications | OR (95% CI) | p | 30–90-day major complications | OR (95% CI) | p |
|----------------------|-----------------------------|------------|--|-----------------------------|------------|--|
|                      |                             |            |   |                             |            |   |
| Age                  |                             | 1.03 (1.01–1.06) | 0.01 | 1.03 (0.99–1.07) | 0.1 |
| Male gender          |                             | 1.4 (0.74–2.79) | 0.3 | 1.49 (0.66–3.82) | 0.4 |
| BMI                  |                             | 1.04 (0.78–1.1) | 0.2 | 1.05 (0.97–1.23) | 0.2 |
| ASA                  |                             | 1.35 (0.6–2.99) | 0.5 | 1.65 (0.66–4.1) | 0.3 |
| ECOG                 |                             | 1.21 (0.63–2.26) | 0.5 | 1.46 (0.71–2.88) | 0.3 |
| CCI                  |                             | 1.19 (1.03–1.37) | 0.01 | 1.24 (1.05–1.47) | <0.01 |
| ERAS                 |                             | 0.77 (0.21–2.23) | 0.6 | 0.72 (0.11–2.69) | 0.7 |
| Diversion            |                             | Conduit    | 1.42 (0.49–5.18) | 0.5 | 3.52 (0.69–64.5) | 0.2 |
|                      |                             | Neobladder | 0.93 (0.27–3.69) | 0.9 | 1.49 (0.22–29.6) | 0.7 |

|                      | 30-day hospitalization | OR (95% CI) | p | 30-day hospitalization | OR (95% CI) | p |
|----------------------|-----------------------|------------|--|-----------------------|------------|--|
|                      |                       |            |   |                       |            |   |
| Age                  |                       | 1.00 (0.95–1.06) | 0.9 | 1.01 (0.98–1.04) | 0.5 |
| Male gender          |                       | 1.32 (0.33–8.82) | 0.7 | 1.39 (0.66–3.23) | 0.4 |
| BMI                  |                       | 1.14 (1.01–1.27) | 0.02 | 1.03 (0.96–1.1) | 0.3 |
| ASA                  |                       | 0.83 (0.08–6.14) | 0.9 | 0.8 (0.3–1.99) | 0.6 |
| ECOG                 |                       | 2.39 (0.56–8.68) | 0.2 | 1.08 (0.49–2.15) | 0.8 |
| CCI                  |                       | 1.13 (0.81–1.49) | 0.4 | 1.13 (0.95–1.32) | 0.1 |
| ERAS                 |                       | 1.5 (0.08–8.58) | 0.7 | 1.37 (0.37–4.01) | 0.6 |
| Diversion            |                       | Conduit    | 0.34 (0.05–6.85) | 0.3 | 3.89 (0.76–71.2) | 0.2 |
|                      |                       | Neobladder | 1.82 (0.28–35.7) | 0.6 | 3.67 (0.64–69.5) | 0.2 |

OR odds ratio, CI confidence interval, BMI body mass index, ASA American Society of Anesthesiologists, ECOG Eastern Cooperative Oncology Group, CCI Charlson comorbidity index; ERAS enhanced recovery after surgery
the identification of patients who are more likely to benefit from a sLAD.

Despite its strengths, our study is not devoid of limitations, which are mainly inherent to its retrospective design. The long time span of the study and missing sLAD in early years may have influenced results. Moreover, different surgeons over time may have also introduced additional bias. sLAD patients had higher rate of NAC which has been suggestive to lead to more difficult dissection and a minimally higher complication rate [20]. Finally, other perioperative pathways that have shown to improve surgical outcomes, i.e., the ERAS protocol [21], were implemented in more recent patients treated mainly with sLAD, influencing, therefore, results.

Conclusions

Our data confirm that while sLAD leads to higher number of nodes removed and resulting higher nodal stage, it does not increase perioperative morbidity. Further studies should focus on the development of risk-adapted models to guide the choice of an individualized LAD template based on clinicopathologic characteristics and patient health status in a shared decision-making process with the patient.

Acknowledgements

Open access funding provided by Medical University of Vienna.

Author contributions

SFS and DA protocol/project development. DA data collection or management and data analysis. DA, MA, FS, KG, AH, PIK, and SFS manuscript writing/editing.

Compliance with ethical standards

Conflict of interest

Nothing to disclose.

Research involving human participants and/or animals and Informed consent

Retrospective analysis, no informed consent needed.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Alfred Witjes J, Lebret T, Compérat EM et al (2016) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475. https://doi.org/10.1016/j.eururo.2016.06.020
2. Vazina A, Dugi D, Shariat SF et al (2004) Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 171:1830–1834. https://doi.org/10.1097/01.ju.0000121604.58067.95
3. Woldu SL, Sanli O, Clinton TN, Lotan Y (2018) Validating the predictors of outcomes after radical cystectomy for bladder cancer. Cancer 34:1945. https://doi.org/10.1002/cncr.31799
4. Abdollah F, Sun M, Schmitges J et al (2012) Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int 109:1147–1154. https://doi.org/10.1111/j.1464-410X.2011.10482.x
5. Bruins HM, Veskimäie E, Hernández V et al (2014) The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol 66:1065–1077. https://doi.org/10.1016/j.eururo.2014.05.031
6. Jensen JB, Ulhøi BP, Jensen KME (2010) Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int 106:199–205. https://doi.org/10.1111/j.1464-410X.2009.09118.x
7. Leissner J, Ghoneim MA, Abol-Enein H et al (2004) Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 171:139–144. https://doi.org/10.1097/01.ju.0000102302.26806.fb
8. Dorin RP, Daneshmand S, Eisenberg MS et al (2011) Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol 60:946–952. https://doi.org/10.1016/j.eururo.2011.07.012
9. Zehnder P, Studer UE, Skinner EC et al (2011) Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 186:1261–1268. https://doi.org/10.1016/j.juro.2011.06.004
10. Gschwend JE, Heck MM, Lehmann J et al (2018) Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol. https://doi.org/10.1016/j.eururo.2018.09.047
11. Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
12. Rink M, Fajkovic H, Cha EK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61:854–855. https://doi.org/10.1016/j.eururo.2011.12.055
13. Brössner C, Pycha A, Toth A et al (2004) Does extended lymphadenectomy increase the morbidity of radical cystectomy? BJU Int 93:64–66
14. Isharn H, Jeldres C, Zini L et al (2009) A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol 182:70–77. https://doi.org/10.1016/j.juro.2009.02.120
15. Shabsigh A, Korets R, Vora KC et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55:164–174. https://doi.org/10.1016/j.eururo.2008.07.031
16. Stitzenberg KB, Chang Y, Smith AB, Nielsen ME (2015) Exploring the burden of inpatient readmissions after major cancer surgery. J Clin Oncol 33:455–464. https://doi.org/10.1200/JCO.2014.55.5938
17. Joice GA, Chappidi MR, Patel HD et al (2018) Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter? BJU Int 96:74–1024. https://doi.org/10.1111/bju.14448
18. Stimson CJ, Chang SS, Barocas DA et al (2010) Early and late perioperative outcomes following radical cystectomy: 90-day
readmissions, morbidity and mortality in a contemporary series. J Urol 184:1296–1300. https://doi.org/10.1016/j.juro.2010.06.007
19. Jensen JB, Ulhoi BP, Jensen KM-E (2012) Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int J Urol 19:39–47. https://doi.org/10.1111/j.1442-2042.2011.02887.x
20. Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. https://doi.org/10.1056/NEJMoa022148
21. Azhar RA, Bochner B, Catto J et al (2016) Enhanced recovery after urological surgery: a contemporary systematic review of outcomes, key elements, and research needs. Eur Urol 70:176–187. https://doi.org/10.1016/j.eururo.2016.02.051

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.